Damora Therapeutics, Inc. (DMRA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Damora Therapeutics, Inc. (DMRA) has a cash flow conversion efficiency ratio of 0.002x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($566.00K) by net assets ($240.38 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See DMRA equity to assets ratio to measure how much of total assets are equity-financed.
Damora Therapeutics, Inc. - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Damora Therapeutics, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Damora Therapeutics, Inc. cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Damora Therapeutics, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Damora Therapeutics, Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Leggett & Platt Incorporated
NYSE:LEG
|
-0.054x |
|
Uniqure NV
NASDAQ:QURE
|
-0.072x |
|
Mayinglong Pharmaceutical Group Co Ltd
SHG:600993
|
0.029x |
|
Aura Investments Ltd
TA:AURA
|
-0.169x |
|
WEBTOON Entertainment Inc. Common stock
NASDAQ:WBTN
|
0.006x |
|
PROG Holdings Inc
NYSE:PRG
|
0.222x |
|
Jungfraubahn Holding AG
SW:JFN
|
0.156x |
|
REX American Resources Corporation
NYSE:REX
|
-0.003x |
Annual Cash Flow Conversion Efficiency for Damora Therapeutics, Inc. (2018–2025)
The table below shows the annual cash flow conversion efficiency of Damora Therapeutics, Inc. from 2018 to 2025. For the full company profile with market capitalisation and key ratios, see Damora Therapeutics, Inc. (DMRA) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $240.38 Million | $-6.73 Million | -0.028x | +97.83% |
| 2024-12-31 | $14.47 Million | $-18.62 Million | -1.287x | -12.72% |
| 2023-12-31 | $32.33 Million | $-36.91 Million | -1.142x | -64.22% |
| 2022-12-31 | $61.75 Million | $-42.93 Million | -0.695x | -55.80% |
| 2021-12-31 | $117.22 Million | $-52.31 Million | -0.446x | -93.30% |
| 2020-12-31 | $165.49 Million | $-38.20 Million | -0.231x | +42.10% |
| 2019-12-31 | $48.47 Million | $-19.33 Million | -0.399x | +10.71% |
| 2018-12-31 | $30.66 Million | $-13.69 Million | -0.447x | -- |
About Damora Therapeutics, Inc.
Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company's lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to u… Read more